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Background: Patients with type 2 diabetes mellitus (T2DM) have increased severity of periodontitis. Toll-like
receptor (TLR)4, its co-receptors CD14 and MD-2, and adaptor MyD88 play pivotal roles in lipopolysaccharide
(LPS)-triggered tissue inflammation and periodontitis. This study investigated the effects of T2DM and periodontitis on
TLR4, CD14, MD-2 and MyD88 mRNA expression in surgically removed periodontal tissues.
Methods: Periodontal tissue specimens were collected from 14 patients without periodontitis and T2DM (Group 1), 15
patients with periodontitis alone (Group 2), and 7 patients with both periodontitis and T2DM (Group 3). The mRNA of
TLR4, CD14, MD-2 and MyD88 was quantified using real-time PCR and compared between the groups.
Results: Statistical analysis showed that periodontal expression of CD14 mRNA was significantly reduced across Groups
1, 2 and 3 (p = 0.02) whereas the mRNA expression of TLR4, MD-2 and MyD88 was not significantly different among
the groups. Furthermore, when patients in Groups 1 and 2 were combined (n = 22), the CD14 mRNA expression was
significantly lower than that in patients of Group 1 (p = 0.04).
Conclusions: CD14 mRNA expression was downregulated across patients with neither periodontitis nor T2DM,
patients with periodontitis alone and patients with both diseases, suggesting that CD14 mRNA expression is associated
with a favorable host response or subjected to a negative feedback regulation.
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Gram-negative bacteria are the major pathogens involved
in periodontitis, which is characterized by inflammatory tis-
sue destruction of tooth-supporting structures [1]. Studies
have established that host immune-inflammatory response
to Gram-negative bacteria-derived lipopolysaccharide (LPS)
plays a pivotal role in the initiation and progression of peri-
odontitis [2]. As a major breakthrough in periodontal re-
search, Beutler and his coworkers discovered in 1998 that
toll-like receptor (TLR)4 is LPS receptor and mediates
LPS-triggered signaling transduction [3]. LPS-triggered
TLR4 activation leads to an increased secretion of* Correspondence: huangyan@musc.edu
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(http://creativecommons.org/publicdomain/zeproinflammatory cytokines, mediators and matrix metallo-
proteinases (MMPs) from a variety of cells including mono-
cytes, macrophages, neutrophils, lymphocytes, and gingival
fibroblasts that contribute to periodontal inflammation and
tissue destruction [4]. In addition to TLR4, studies have
well documented that TLR4 co-receptors CD14 and MD-2
as well as TLR4 adaptor proteins such as myeloid differenti-
ation primary response gene 88 (MyD88) are also vitally in-
volved in LPS-triggered inflammatory signaling [5–8].
It has been well established that periodontitis is
more prevalent and severe in patients with poorly
controlled type 2 diabetes mellitus (T2DM) than non-
diabetic individuals [9–11]. Findings from mechanistic
studies indicate that poorly controlled T2DM leads to
a hyperinflammatory host response to periodontal
microbiota and also impairs resolution of inflamma-
tion and repair, leading to accelerated periodontal de-
struction [10]. In line with these notions, increasedicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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MMP-8 across patients with neither periodontitis nor
T2DM, patients with periodontitis alone and patients
with both diseases was reported by our group [12–14].
Furthermore, we have also demonstrated through our
in vitro studies that high glucose enhances LPS-triggered
expression of proinflammatory genes in macrophages
and gingival fibroblasts [15–19], indicating that
T2DM-associated factors such as hyperglycemia en-
hance periodontal inflammation and tissue destruction
and thus exacerbate periodontitis.
In the studies to understand how T2DM increases
host responsiveness to LPS, it has been shown that
T2DM increases the expression of TLR4 in host cells
such as monocytes [20, 21]. Given that TLR4 is the re-
ceptor for LPS, it is plausible that upregulation of TLR4
expression on cell surface renders more binding sites for
LPS and thus increases cell response to LPS challenge.
Therefore, it is important to determine if T2DM in-
creases host responsiveness to LPS by enhancing the ex-
pression of TLR4 and TLR4-associated proteins in
periodontal tissue. However, the effect of T2DM on peri-
odontal expression of TLR4 and TLR4-associated pro-
teins in patients with periodontitis has not been well
established.
In this study, we hypothesized that the expression
of TLR4 or TLR4-associated molecules such as CD14,
MD-2 and MyD88 are regulated by periodontitis and
T2DM. To test our hypothesis, we collected peri-
odontal tissues from patients with or without peri-
odontitis and T2DM at the time of necessary
surgeries and determined the mRNA expression of
TLR4, CD14, MD-2 and MyD88 using quantitative
real-time polymerase chain reaction (PCR).
Methods
Patients
Thirty-six patients were selected from a population re-
ferred to the Post-doctoral Periodontics Program in the
College of Dental Medicine at the Medical University of
South Carolina, Charleston, South Carolina. Patients re-
cruited included 14 individuals who did not have peri-
odontitis and T2DM (group 1), 15 patients with
periodontitis only (group 2), and 7 patients with both
diseases (group 3). The patients in group 1 who required
non-periodontal disease-related surgeries, such as crown
lengthening and extractions served as controls. All the
tissues collected were periodontal tissues taken as collars
from the gingival margin to include both epithelium and
connective tissue.
The patients from group 2 and group 3 met the fol-
lowing diagnostic criteria for periodontitis [12–14]: A
periodontal probing depth (PD) of ≥ 5 mm at two or
more teeth, or clinical attachment level (AL) of ≥ 5 mmat two or more teeth. The exclusion criteria were as fol-
lows: Patients who were pregnant or unsure about preg-
nancy status, serum creatinine ≥ 1.6 mg/dL, abnormal
hepatic function, hemoglobinopathy (sickle cell trait/
hemolytic anemia) interfering with hemoglobin A1c
(HbA1c) monitoring, aggressive periodontitis, platelet
and coagulation disorders, and/or unwillingness to sign
the informed consent form or enter the study. An oral
examination including periodontal PD and clinical AL
was performed. Six sites (mesio-buccal, buccal, disto-
buccal, disto-lingual, lingual and mesio-lingual) were ex-
amined for each tooth, excluding third molars. Probing
depth was defined as the distance from the free gingival
margin to the bottom of the sulcus while gingival reces-
sion was defined as the distance from the cementoena-
mel junction to the free gingival margin. Clinical AL was
calculated as the sum of PD and gingival recession. The
patients in groups 2 and 3 had periodontal surgery for
the treatment of periodontitis and their periodontal tis-
sue, including epithelium and connective tissue, were re-
moved from sites based on the greatest PD and/or AL.
The PD and AL reported in this study were related to
the surgery sites. The HbA1c test was carried out on all
patients to document their glycemic status. T2DM was
diagnosed previously for all patients in Group 3. All pa-
tients provided informed consent for specimen collection.
The study protocol and consent forms were approved by
the Medical University of South Carolina’s Institutional
Review Board (Approval number: Pro00010000).
Isolation of RNA and RNA Reverse Transcription (RT)
Total RNA was isolated from periodontal tissue specimens
using the RNeasy minikit (Qiagen, Santa Clarita, CA). The
first-strand complementary DNA (cDNA) was synthesized
with the iScript™ cDNA synthesis kit (Bio-Rad, Hercules,
CA) by following the instruction provided by the manufac-
turer. The reaction was cycled for 5 min at 25 °C, 30 min at
42 °C and 5 min at 85 °C using a PTC-200 DNA Engine
(MJ Research, Waltham, MA).
Quantitative real-time PCR
The RT reaction mixture from the above experiments
was then subjected to real-time PCR amplification. The
Beacon Designer Software (PREMIER Biosoft Inter-
national, Palo Alto, CA) was used for designing primers
(Table 1). Primers were synthesized by Integrated DNA
Technologies, Inc. (Coralville, IA). PCR was carried out
in duplicates using a 25 μl reaction mixture that con-
tained 1.5 μl RT reaction mixture, 0.2 μM of both
primers and 12.5 μl of iQ™ SYBR Green Supermix (Bio-
Rad). The PCR reaction was performed with the iCycler™
Real-Time Detection System (Bio-Rad). Forty cycles con-
sisting of denaturation (95 °C for 10 s) and annealing/ex-
tension (56 °C for 45 s) were run. A melt-curve
Table 1 The primer sequences for real-time PCR
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1 min and then temperature is increased by 0.5 °C every
10 s) to detect the primer dimers. Data were analyzed
with the SmartCycler II software. The average threshold
cycle (Ct) of fluorescent units was used for analysis.
Quantification was calculated using the Ct of the target
signal relative to that of glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) signal in the same RNA sample.
Statistical analysis
The age, gender and race of the study participants are
presented as counts and the continuous variables are
presented as medians. The GraphPad Instat 3 software
(GraphPad Software, Inc., San Diego, CA) was used for
statistical analysis. Nonparametric analyses testing for
any differences in continuous variables among groups
greater than two were performed using the Kruskal-
Wallis procedure. Nonparametric analysis testing for any
difference in variables between two groups was per-
formed using the Mann-Whitney procedure. A value of
p < 0.05 was considered significant. The correlation ana-
lysis on the relationship between CD14 mRNA expres-
sion and PD, AL or HbA1c was evaluated by Pearson’s
method. Our previous studies have indicated that the
sample size of 7 or greater provided sufficient power
to detect the difference of periodontal mRNA expres-
sion of IL-6 and MMP-8 across control individuals
who did not have periodontitis and T2DM, patients
with periodontitis alone and patients with both peri-
odontitis and diabetes [13, 14].Table 2 Patients and periodontal disease in three groups
Group 1: Patients with
diabetes and periodon
Patient number 14
Age 58 ± 11
Gender (male/female) 11/3
Race and ethnicity
Caucasians/African Americans (nonhispanic) 6.0 (12/2)
Smoking status (smokers/nonsmokers) 0.4 (4/10) +
HbA1c (%) 5.81 ± 0.55
PD (mm) 2.45 ± 0.86 +
AL (mm) 2.48 ± 0.89 +
The data are mean ± SD. *p < 0.05 vs group 1 or group 2; +p < 0.05 vs group 2 or grResults
Study population
The clinical data for patient age, gender, race, smoking
status, HbA1c, periodontal PD, and AL were presented
in Table 2.
Age - The ages of subjects in groups 1, 2, and 3 ranged
from 42 to 79, 40 to 79, and 52 to 71 with a mean ±
standard deviation of 58 ± 11, 56 ± 11, and 63 ± 6, re-
spectively. No significant difference between groups was
found.
Gender - The ratios of male/female gender in groups
1, 2, and 3 were 3.7 (11/3), 2 (10/5), and 7 (7/0), respect-
ively. No significant difference was found between the
groups.
Race - The ratios of Caucasians vs. African Americans
in groups 1, 2, and 3 were 6.0 (12/2), 2.8 (11/4), and and
0.17 (1/6), respectively. Statistical analysis indicated that
African Americans in group 3 were significantly more
than those in group 1 or group 2, which is consistent
with the previous reports that African Americans have a
high risk of developing T2DM and periodontitis [22, 23].
Smoking status - The smoker/nonsmoker ratios in
groups 1, 2, and 3 were 0.4 (4/10), 1.5 (9/6), and 2.5 (5/2),
respectively. Statistical analysis indicated that smokers in
group 2 and group 3 were significantly more than
those in group 1, which is consistent with the previ-
ous reports that smoking is associated with a high
risk for periodontitis [24].
Periodontitis - The PD in groups 1, 2 and 3 was 2.45 ±
0.86, 4.20 ± 2.00 and 4.80 ± 2.32 mm, respectively. The
AL in groups 1, 2 and 3 was 2.48 ± 0.89, 5.03 ± 2.48
and 5.24 ± 2.39 mm, respectively. A significant differ-
ence of PD and AL was found between group 1 and
group 2 or group 3, but no significant difference of
PD and AL was found between group 2 and group 3.
Diabetes - All patients in group 3 reported having
T2DM. The mean HbA1c in Groups 3 ranged from 7.0 %
to 10.7 % with a mean ± standard deviation of 8.19 ±
1.24 % that is significantly higher than 5.81 ± 0.55 % andout
titis
Group 2: Patients with
periodontitis alone
Group 3: Patients with both
periodontitis and diabetes
15 7
56 ± 11 63 ± 6
10/5 7/0
2.8 (11/4) 0.17(1/6) *
1.5 (9/6) 2.5 (5/2)
5.60 ± 0.56 8.19 ± 1.24 *
4.20 ± 2.00 4.80 ± 2.32
5.03 ± 2.48 5.24 ± 2.39
oup 3. PD Probing depth, AL Attachment level
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of the seven patients were prescribed metformin alone or
in combination with Glucotrol (Glipizide, Pfizer) or NPH
insulin (Humulin, Eli Lily and Company). One patient was
prescribed insulin Glargine (Lantus, Sanofi-Aventis), one
patient was prescribed insulin Aspart (NovoLog, Novo
Nordisk), and one patient did not report taking any medi-
cation for diabetes.Periodontal expression of CD14, TLR4, MD-2 and MyD88
in three groups
The expression of CD14, TLR4, MD-2, and MyD88 in
surgically removed periodontal tissues was successfully
quantified using real-time PCR. As shown in Table 3,
CD14 expression was highest among four genes in pa-
tients without periodontitis and T2DM (Group 1). Our
statistical analysis using nonparametric Kruskal-Wallis
test showed that the periodontal expression of TLR4,
MD-2 and MyD88 had no significant difference among
the 3 groups. Interestingly, CD14 expression was found to
be significantly downregulated across Groups 1, 2 and 3
(p = 0.020). We also compared the CD14 expression
between two groups. Results showed that although
CD14 expression in Group 2 (patients with periodon-
titis alone) is lower than that in Group 1 (patients
without both periodontitis and T2DM), the difference
is not statistically significant. However, when the
patients in Group 2 were combined with Group 3
(patients with both periodontitis and T2DM), the
CD14 expression was significantly lower than that in
Group 1 (p = 0.04) (Table 4). Furthermore, we found
that CD14 expression in Group 3 is significantly
lower than that in Group 1 (p = 0.003), indicating that
periodontal CD14 expression in patients with both
periodontitis and T2DM is significantly lower than
that in patients without periodontitis and T2DM.Table 3 Periodontal expression of CD14, TLR4, MD-2 and MyD88 in







CD14 1.92 1.39 0.68
(0.78, 11.88) (0.30, 17.80) (0.17
TLR4 0.74 0.58 0.74
(0.28, 5.25) (0.15, 18.31) (0.14
MD-2 0.46 0.35 0.50
(0.21, 2.96) (0.04, 5.76) (0.19
MyD88 0.81 0.61 0.71
(0.50, 1.21) (0.22, 2.19) (0.45
Data presented are medians (minimum, maximum)The relationship between CD14 mRNA expression and PD,
AL or HbA1c
The relationship between CD14 mRNA expression and
PD, AL or HbA1c was statistically analyzed and no sig-
nificant correlations were found between CD14 mRNA
expression and these clinical parameters (Table 5).
Discussion
Our current study demonstrated that CD14 mRNA level
was significantly reduced across patients with neither
periodontitis nor T2DM, patients with periodontitis
alone, and patients with both periodontitis and T2DM,
suggesting that periodontitis and T2DM negatively regu-
lates CD14 gene expression in periodontal tissue. Our
findings are consistent with those by Jin et al., who re-
ported that the CD14 protein level in gingival biopsy tis-
sues from patients with periodontitis was significantly
lower than that in subjects without periodontitis [25].
They also reported that the level of secreted CD14 in
gingival crevicular fluid (GCF) was lower in patients
with more deep pockets than that in patients with less
deep pockets [26]. Since their studies were focused on
CD14 protein level in periodontal tissue, it remains un-
clear if the decreased CD14 protein level is the result of
downregulation of CD14 mRNA expression that may
suggest the involvement of transcriptional regulation of
CD14 expression. Our current study has provided the
new insight into the mechanisms involved in the regula-
tion of CD14 expression.
In the current study, we employed real-time PCR tech-
nique to quantify the mRNA expression level of TLR4,
CD14, MD-2 and MyD88 in periodontal tissue. It is well
known that regulation of cytokine expression at the
mRNA level via nuclear factor-kappa B (NFκB)-mediated
transcriptional activation plays a crucial role in peri-
odontitis [27]. Therefore, studies investigating gene
expression at the mRNA levels are important forthree groups
p 3 (n = 7) Nonparametric analyses (Kruskal-Wallis test)












Table 4 The difference of CD14 expression between patients in Group 1 and combined patients in Group 2 and Group 3
Group 1 (patients
without periodontitis)
Combination of Group 2
(patients with periodontitis alone) and Group 3
(patients with both periodontitis and diabetes)
Two-tailed
P value
Patient number 14 22 0.04
Median (minimum, Maximum) 1.92 (0.78, 11.88) 1.22 (0.17, 17.80)
Data presented are medians (minimum, maximum)
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the pathogenesis of periodontitis. Furthermore, since
real-time PCR is a fully quantitative method and well
controlled by normalization to the housekeeping gene,
the data are valuable for assessment of gene expression.
In addition to real-time PCR quantification of gene ex-
pression at the mRNA level, immunohistochemistry and
immunofluorescence are also commonly employed in
the studies of gene expression at the protein level. While
these methods have advantages in the characterization
of tissue or cell specific gene expression at the protein
level, they also have disadvantage as a semi-quantitative
approach [28] that may lead to inter-study variability.
For example, by using immunohistochemistry, one study
showed that periodontitis decreased TLR4 [29] but an-
other study demonstrated that periodontitis increased
TLR4 level in the gingival epithelium [30].
CD14 was characterized as LPS receptor in 1990 [31],
almost a decade before the discovery of TLR4. While
TLR4 has a transmembrane domain for LPS-triggered
signal transduction, CD14 lacks the transmembrane do-
main and is unable to transmit LPS signaling. CD14 is
anchored with glycosylphosphatidylinositol (GPI) on the
cell surface and expressed as a 55-kDa glycoprotein [32].
In addition to the membrane-bound form (mCD14),
CD14 is also expressed as a soluble form (sCD14) by se-
cretion of CD14 without coupling to the GPI anchor or
from shedding or cleavage from mCD14 [33]. The major
function of CD14 is to serve as an initial receptor for
LPS and facilitate the binding of LPS to TLR4/MD-2
complex [34]. In addition, CD14 also recognizes other
pathogen-associated molecular patterns such as lipotei-
choic acid [35].
Previous studies have shown that CD14 has dual roles
in response to Gram-negative bacteria [36]. For exam-
ples, one study showed that neutralization of CD14 pre-
vented LPS-induced uncontrolled proinflammatoryTable 5 The relationship between CD14 mRNA expression and
PD, AL or HbA1c
PD AL HbA1c
CD14 mRNA expression n 36 36 36
r -0.1271 -0.1862 -0.1967
p 0.4602 0.2770 0.2500
PD Probing depth, AL Attachment levelresponse and subsequent host death [37], revealing a
proinflammatory effect of CD14. Another study, how-
ever, reported that when CD14 was blocked, animals in-
fected with Shigella, a diarrheal pathogen, exhibited a
50-fold increase in bacterial invasion and more severe
tissue injury compared with animals without CD14
blocking [38], indicating an anti-inflammatory effect of
CD14. These studies suggest that while downregulation
of periodontal CD14 expression reduces the stimulatory
effect of LPS on proinflammatory signaling, it may also
impair the innate immunity against LPS-independent
pathogens and thus increases tissue inflammation.
Previous studies have also shown the dual roles of
CD14 in T2DM. On one hand, it was reported that
CD14 expression was significantly associated with
T2DM and correlated with serum concentrations of C-
reactive protein [39]; On the other hand, it was reported
that injection of recombinant human soluble CD14 to
diabetic mice increased insulin action [40] and the mice
with CD14-deficiency displayed significant glucose in-
tolerance [41], suggesting a beneficial role of CD14 in
insulin signaling and glucose homeostatsis.
The finding that CD14 was downregulated in patients
with periodontitis may also reveal a negative feedback
mechanism by which periodontal tissue of patients with
periodontitis prevent further damage from repeated at-
tacks by bacteria-derived LPS. Interestingly, Nemoto
et al. reported that CD14 expression on human gingival
fibroblasts (HGFs) was markedly reduced by phorbol
12-myristate 13-acetate (PMA)-activated polymorpho-
nuclear leukocytes (PMNs) in a coculture system of
HGF and PMNs [42]. Their further investigation
showed that as a result of CD14 reduction, LPS-
induced production of inflammatory cytokines such as
IL-8 by HGFs was suppressed. These findings sug-
gested that while activated PMNs play a crucial role
in tissue inflammation, HGFs have a potential nega-
tive feedback mechanism to control inflammation by
downregulation of CD14 expression.
In addition to CD14, our current study also examined
the periodontal expression of TLR4, MD-2 and MyD88.
Results showed that the periodontal mRNA expressions
of TLR4, MD-2 and MyD88 had no significant difference
across the 3 groups. While our current study is the first
one focusing on TLR4 mRNA expression, Promsudthi
et al. and Rojo-Botello et al. have reported the effect of
Hedgpeth et al. BMC Oral Health  (2015) 15:145 Page 6 of 7T2DM and chronic periodontitis on TLR4 protein ex-
pression [29, 30]. Promsudthi et al. showed that patients
with periodontitis had reduced TLR4 protein in gingival
epithelium, but patients with both periodontitis and dia-
betes had statistically significant higher percentages of
TLR4-positive cells as compared with periodontally
healthy subjects [29]. Rojo-Botello et al. demonstrated
that patients with periodontitis and diabetes had a
higher TLR4 protein in gingival epithelium than patients
with periodontitis alone. Obviously, these studies fo-
cused on the periodontal TLR4 protein expression, but
our study aimed at the TLR4 mRNA expression.
It has been well documented that CD14 expression is
upregulated by LPS and inflammatory cytokines in vitro
[43–45]. However, the mechanisms involved in the
downregulation of CD14 expression have not been well
established. In addition to the inhibition of CD14 ex-
pression by PMNs as described above, Imai et al. have
reported that transforming growth factor beta (TGFβ)1
is capable of inhibiting LPS-stimulated CD14 expression
in macrophages by reducing transcription factor activat-
ing protein (AP)-1 [46]. Interestingly, our recent study
has shown that periodontal TGFβ1 expression is in-
creased in patients with periodontitis [47]. Therefore, it
is likely that TGFβ1 plays a role in the downregulation
of periodontal CD14 expression in patients with peri-
odontitis. Nevertheless, it remains unclear how CD14
expression is further downregulated by T2DM and more
studies are necessary to elucidate the mechanisms by
which periodontal CD14 expression is downregulated by
periodontitis and T2DM.
Conclusions
CD14 expression was downregulated across patients
with neither periodontitis nor T2DM, patients with peri-
odontitis alone, and patients with both periodontitis and
T2DM. This finding indicates that CD14 expression is
associated with a favorable host response or subjected to
a negative feedback regulation.
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